Stocktoria
CITIUS ONCOLOGY, INC. CTOR
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2022-10-14
Chart by TradingView
3/9
Piotroski F — financial health
-4.22
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Financials | |||||
| Operating income | -$23.5M | -$20.6M | -$1.0M | — | -$138,115 |
| Net income | -$24.8M | -$21.1M | $2.4M | -$12.7M | $380,811 |
| Operating cash flow | -$5.5M | $126,353 | -$601,304 | — | -$47,968 |
| Total assets | $100.9M | $84.4M | $72.6M | $47.7M | $68.2M |
| Total liabilities | $56.1M | $38.2M | — | $22.2M | — |
| Shareholders' equity | $44.9M | $46.1M | $22.7M | $25.5M | $345,508 |
| Ratios | |||||
| Return on assets | -24.5% | -25.1% | 3.3% | -26.6% | 0.6% |
| Return on equity | -55.2% | -45.8% | 10.6% | -49.7% | 110.2% |
| Current ratio | 0.56 | 0.34 | 0.03 | 0.37 | 11.85 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -4.22 (distress)
- Working capital / assets -0.217
- Retained earnings / assets -0.634
- EBIT / assets -0.233
- Equity / liabilities 0.8
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001851484 · as of 2025-09-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.